Exercise in older women with breast cancer during systemic therapy: study protocol of a randomised controlled trial (BREACE)

Hogni Hammershaimb Andersen 1, 2, Marta Kramer Mikkelsen, 2, 3, Ida Lundager, 1, Cecilia Margareta Lund, 4, Julia Sidenius Johansen, 2, 4, 5, Anders Vinther, 1, 6, Carsten Bogh Juhl, 7, 8, Bo Zerahn, 9, Anne-Mette Ragle, 1, Dorte Lisbet Nielsen 2, 5

ABSTRACT

Introduction Exercise interventions have been widely investigated in patients with cancer and demonstrate beneficial effects. However, intervention studies that include older women with breast cancer exercising during medical treatment are scarce. Hence, the aim of this study is to investigate the effect of a 12-week exercise-based intervention in older women (≥65 years) with breast cancer receiving (neo)adjuvant or first-line or second-line systemic therapy.

Methods and analysis This is a single-centre, two-armed randomised controlled trial. We anticipate including 100 patients, who will be randomised 1:1 to exercise-based intervention or control stratified by treatment setting ((neo)adjuvant or metastatic) and treatment (chemotherapy or endocrine therapy + cyclin-dependent kinase (CDK) 4/6 inhibitors). The intervention group will receive standard oncological treatment and a 12-week supervised exercise-based intervention comprising a progressive resistance exercise programme two times per week, a protein supplement after exercise and a home-based walking programme based on daily step counts. The control group will receive standard oncological treatment. Assessments will be performed at baseline and 6, 12 and 24 weeks after start of the intervention. Primary outcome is physical function, measured by the 30-second Chair Stand Test. Secondary outcomes are feasibility (compliance and adherence to intervention), objective and patient-reported functional measures (6-meter and 10-meter gait speed; 6-min Walk Test; Handgrip Strength; Stair Climb Test; Physical Activity Questionnaire), symptom burden and well-being (MD Anderson Symptom Inventory; Hospital Anxiety and Depression Scale), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 and B23), body composition (dual-energy X-ray absorptiometry scan), side effects, inflammatory biomarkers, hospitalisation and survival.

Ethics and dissemination The protocol was reviewed and accepted by the Scientific Ethics Review Committee of the Capital Region of Denmark, 17 June 2018 (VEK ref.: H-18021013). Trial results will be submitted for publication in a peer-reviewed journal and presented on conferences, in oncology wards, exercise centres in municipalities and patient organisations, ensuring dissemination to relevant stakeholders.

INTRODUCTION

Cancer and age

Breast cancer is the most frequent type of cancer among women and is a major cause of cancer-related disability and deaths worldwide. It is estimated that about 2.1 million new cases of breast cancer in women occurred worldwide in 2018. 1 The risk of breast cancer increases with age. The median age at time of diagnosis is 61 years, and 30% of patients with breast cancer are >70 years. 2 Ageing is closely associated with comorbidity. 3 4 More than 50% of older cancer survivors have a comorbidity, and more than four chronic conditions are seen in 25% of older women with breast cancer >65 years. 3 4 These conditions often lead to functional impairment; poorer survival and a decline in quality of life (QoL) and mental, physical and social health. 3 4 Compared with an age-matched population without a history of cancer, the prevalence of the above-mentioned impairments is significantly
higher in cancer survivors: limitations in activities of daily living (ADL) 26.9% versus 31.9%, poor or fair self-rated health 20.9% versus 27.4% and prevalence of geriatric syndromes 53.9% versus 60.8%, respectively.2 3 Furthermore, the negative effects of primary sarcopenia, defined as age-related loss of muscle mass,4 may increase in patients with cancer due to cancer-related cachexia, resulting in decreased treatment tolerability, increased risk of postoperative complications and poorer survival.4 5 In women with breast cancer, antineoplastic treatment may increase muscle atrophy and decrease mitochondrial function, which also have a negative effect on survival.9 10 Although breast cancer among older women is associated with a more favourable tumour biology, Danish patients with breast cancer over the age of 70 years have a poorer prognosis and increased mortality compared with patients with breast cancer treated with (neo)adjuvant or first-line palliative therapy.12 13 14

Exercise interventions

Exercise interventions have been shown to be effective in preventing or relieving cancer symptoms and side effects from cancer treatment.12 15 Furthermore, several studies including different exercise interventions (eg, aerobic exercise or resistance exercise) have shown improved physical and mental health, QoL, muscle strength, physical function and reduced fatigue in patients with cancer.13–15 Nevertheless, very few trials have investigated the effect of exercise interventions in older women with breast cancer receiving chemotherapy or therapy for advanced/metastatic disease.16 17 This article describes the protocol of the Breast Cancer Exercise (BREACE) study. The Standard Protocol Items: Recommendations for Interventional Trials checklist for interventional trials and the Consensus on Exercise intervention Recommendations for Interventional Trials checklist were used as reporting guidelines.18 19

METHODS AND ANALYSIS

Aim

The aim of this study is to investigate the feasibility and effect of an exercise-based intervention among older women with breast cancer receiving antineoplastic treatment.

Hypothesis

We hypothesise that (1) the exercise intervention in this trial will improve muscle strength and physical function, decrease weight loss and muscle wasting, reduce symptoms and side effects from the medical treatment, and improve QoL, mental, and physical health compared with the control treatment; (2) the recruitment of the patients will be difficult, especially because of side effects to medical treatment and age-related burdens and (3) a considerable attrition rate will occur, which is in line with prior studies investigating the effect of exercise-based interventions in older cancer survivors, which have experienced relatively high numbers of dropouts during intervention.

However, we expect that the intervention will be feasible and effective due to it targeting the specific needs of the older patient with breast cancer treated with (neo)adjuvant or first-line or second-line palliative therapy and that it can be integrated into the future treatment of this group in both hospital and home settings.

Design

BREACE is one of the five studies in the TOLCA project (Translational and clinical research focused on older patients with cancer), which aims to improve patient survival and QoL. BREACE is a single-centre, two-armed randomised controlled trial. Intervention time will be 12 weeks, mainly comprising a progressive resistance exercise intervention for older women (≥65 years) with breast cancer treated with neo or adjuvant or first-line or second-line palliative systemic therapy at the Department of Oncology at Copenhagen University Hospital, Herlev and Gentofte, Denmark (figure 1). A minimum of 29 evaluable patients will be included in each group, based on a sample size calculation. Since some patients are expected to drop out before evaluation, we anticipate inclusion of up to 100 participants in the study.

The BREACE study is an ongoing study. The first participant was included on 15 November 2018. Recruitment is currently planned until 31 August 2021.

Figure 1 Study design for the Breast Cancer Exercise study, from patient screening to 24 weeks of follow-up.
Participants

Due to low inclusion rates, an amendment to the protocol was made, broadening the inclusion criteria. Age at entry was lowered from ≥70 years to ≥65 years. In addition to adjuvant treatment, neoadjuvant and first-line to second-line treatments were also included.

Patients eligible

Patients eligible for inclusion in this trial must (1) be diagnosed with primary breast cancer and scheduled for neoadjuvant chemotherapy, ± human epidermal growth factor receptor 2 (HER2) inhibitor, ± anthrational treatment; (2) have undergone surgery for primary breast cancer within 12 weeks and received adjuvant chemotherapy, ±HER2 inhibitor, ± anthrational treatment; (3) have advanced or metastatic breast cancer and receive first-line or second-line palliative chemotherapy, ±HER2 inhibitor, or anthrational treatment, +cyclin-dependent kinase (CDK) 4/6 inhibitor; (4) have a performance status (PS) score ≤2 (based on the Eastern Cooperative Oncology Group (ECOG)), see online supplemental file 1; (5) be ≥65 years of age at the time of signing the informed consent form, see online supplemental file 2; and (6) speak and read Danish.

Exclusion criteria

Exclusion criteria: (1) conditions preventing participation in the exercise intervention, including, but not restricted to, severe pain and physical and/or mental impairments; (2) documented and uncontrolled brain metastases; (3) coexisting types of cancer; (4) cognitive impairments that hinder informed consent; (5) medical conditions that could be negatively affected by the intervention including, but not restricted to, congestive heart failure (NYHA class III–IV), unstable angina pectoris, implantable cardioverter defibrillator or myocardial infarction within 6 months and (6) bone metastasis which could increase the risk of injuries caused by the exercise intervention.

The primary investigator will identify potentially eligible patients, and an oncologist will assess the eligibility of patients based on the inclusion and exclusion criteria. Eligible patients will hereafter be informed about the study and asked whether they would be interested in further contact. If interested, patients will be contacted, thoroughly informed about the study and their rights in light of the Declaration of Helsinki, and potentially included by the primary investigator.

Randomisation

The allocation sequence will be developed by a statistician with no involvement in the study. Patients included in the study will be randomised 1:1 to either the intervention group or the control group. Stratification will be performed at randomisation by cancer stage ((neo) adjuvant or metastatic), and treatment (chemotherapy or endocrine therapy ±CDK 4/6 inhibitors) as this is expected to have an influence on the results. Randomisation and stratification will be performed through the randomisation module in the web-based research platform Research Electronic Data Capture.

Intervention

Acknowledging exercise recommendations from the Cancer and Aging Group,16 patients in the intervention group will receive an exercise-based intervention in addition to standard oncological care. The intervention will comprise a 12-week supervised group-based exercise programme, mainly focusing on progressive resistance training (PRT) (figure 2), and a nutrition supplement (eg, protein drink). In addition, an individual light-to-moderate home walking programme, based on step counts and monitored by a pedometer, is included to avoid inactivity. The PRT and walking programme will be individually tailored by experienced physiotherapists who will consider any relevant comorbidities and/or cancer-related (eg, bone metastasis), motivational, physical or psychological factors.

The 12-week supervised group-based intervention will comprise participation in the supervised exercise programme two times per week (60 min/session). The

<table>
<thead>
<tr>
<th>Duration of exercise program</th>
<th>60 min. (warm-up 15 min., PRT 35 min., cool down/stretching 10 min.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of repetitions (PRT)</td>
<td>15-12 RM (week 1-3), 12 RM (week 4-6), 10 RM (week 7-9), 8 RM (week 10-12)</td>
</tr>
<tr>
<td>No. of sets (PRT)</td>
<td>2 (week 1-3), 3 (week 4-12)</td>
</tr>
<tr>
<td>Resting period between sets (PRT)</td>
<td>40-60 sec.</td>
</tr>
<tr>
<td>Resting period between sessions</td>
<td>2-4 days</td>
</tr>
<tr>
<td>Intervention period</td>
<td>12 weeks</td>
</tr>
</tbody>
</table>

Figure 2  A detailed description of the supervised exercise programme. PRT, progressive resistance training; RM, repetition maximum.
exercise programme will include a warm-up session, focusing mainly on light-to-moderate intensity exercise, flexibility and balance exercises recommended and tailored for this group (15 min), a PRT programme performed on seven resistance training machines targeting the large muscle groups (low row, knee flexion, chest press, abdominal crunch, knee extension, back extension and leg press (35 min)) (figure 2), followed by cool down, stretching and relaxation (10 min). The PRT will be initiated with low load and high repetition numbers and progresses in week 3 from 2 to 3 sets and from 15 to 8 repetition maximum during the 12-week intervention (figure 2). The PRT follows recommendations from the American College of Sports Medicine (ACSM) (20-22). If necessary, a conservative approach to the recommendations for PRT for older adults will be used, based on assessment by experienced physiotherapists (20, 22).

The supervised exercise training will take place at the Department of Physiotherapy and Occupational Therapy at Herlev and Gentofte Hospital and be led by experienced physiotherapists. Furthermore, patients in the intervention group will receive a ‘replacement training programme‘ comprising a few effective exercises for the major muscle groups that can be performed at home. If a patient cancels a group-based training session during the intervention period, the patient will be instructed to perform the exercises in the replacement programme instead. Patients will be thoroughly introduced to these replacement exercises when entering the study. A nutritional supplement (protein drink) is offered after each exercise session, containing 8 or 12 g of protein and 300 kcal, consumed immediately after the exercise session, supervised by the physiotherapists. Furthermore, a walking programme tailored individually to each patient and based on daily step counts, measured by a GARMIN vivofit V.4 wristwatch, will be included. The mean of 3 days step count measured pre intervention will be used as starting point. A weekly goal for each patient will be set once a week by the patient and the primary investigator. Although the goal is to increase the patient’s physical activity, the weekly goal can be increased, maintained or decreased from the previous week, based on motivation, physical and psychological state, which could be negatively affected by the cancer treatment.

Control group
Patients randomised to the control group will receive standard oncological care, including information about physical activity which will not be restricted, due to ethical considerations.

Assessments
Data collection and test for both groups will be performed at baseline, midintervention (6 weeks), post intervention (12 weeks) and follow-up (24 weeks) (table 1).

To minimise dropouts, the exercise intervention will be supervised, and participants exercise in groups with a possibility to interact and socialise with each other. In addition, the primary investigator will be present, but not involved, in all test seances for all participants, whenever possible. Furthermore, exercise and test will be coordinated with other visits to the hospital to avoid additional hospital visits.

Primary outcome
The primary outcome is the 30-second Chair Stand Test (30s-CST) and will be used to measure physical function and lower extremity strength (see online supplemental file 3). The 30s-CST is deemed valid and reliable to measure lower body strength and function among healthy older adults and has been used and tested in patients with cancer. Furthermore, the 30s-CST has frequently been used in measuring physical capacity in older people and as an indicator for functional independence.

Secondary outcomes
Feasibility measures
Feasibility measures (acceptability, attrition and adherence to the study) will be evaluated by attendance rate to the intervention in %. Reasons for declining participation or dropout will be obtained by asking the patients.

Physical function
A 6-meter gait speed test and 10-meter gait speed test at normal and maximum gait speed will be used to measure physical performance, the 6-minute Walk Test to measure physical capacity and endurance, the Handgrip Strength Test (Grip SAEHAN DHD-1 Digital Hand Dynamometer) to measure physical function of the upper body, and a Stair Climb Test to measure lower extremity muscle power (further descriptions of the physical function tests in online supplemental file 3).

Patient-reported outcome measures
Patient-reported outcome measures will mainly comprise questionnaires measuring symptom burden (MD Anderson Symptom Inventory (MDASI)), QoL (The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and the breast cancer-specific module), depression and anxiety (The Hospital Anxiety and Depression Scale) and physical activity level (Saltin-Grimby Physical Activity Level Scale). Patient-reported PS will be assessed using the ECOG Scale.

Therapy tolerance
Therapy tolerance will be registered as completion of scheduled (chemo)therapy, dose reductions, treatment discontinuations and toxicity based on information obtained from patient records.

Body composition
Whole-body dual-energy X-ray absorptiometry scan and bioelectrical impedance will be used to assess body composition and hydration status and include data on weight, height and body mass index (BMI).
Biomarkers

Overall, 30 mL blood will be drawn at baseline and 6, 12 and 24 weeks after start of the intervention. Serum C reactive protein (CRP) (liquid assay reagent by an immunoturbidimetric method on a fully automated chemistry analyser from Kit-test SENTINEL CRP Ultra), interleukin 6 (ELISA from Quantikine HS600B, R&D Systems, Abingdon, UK), YKL-40 (ELISA from Quidel, San Diego, California, USA), growth differentiation factor 11 (GDF11), and GDF15 will be analysed. Furthermore, 92 proteins associated with inflammation, immunology and cancer will be analysed using the Olink immuno- oncology protein panel (www.olink.com), a multiplex immunoassay using proximity extension assay. Blood samples and data on biomarkers will be obtained only in patients who have also accepted participation in the PRIMA B (Prospective Collection of blood samples from patients with breast cancer) trial.
collection of bloodsamples from patients with breast cancer) biomarker trial (VEK ref.: KA-H-3-2014-120).

**Hospital admissions**
Hospital admissions will include length of stay and numbers and causes of hospital admissions. All contacts to the emergency room will be registered.

**Mortality/survival**
Incidents of deaths and cause of death (cancer related and non-cancer related) will be registered throughout the study period.

**Data registration**

**Clinical and medical data**
Medical records will be used to obtain patient data on time of breast cancer diagnosis, disease stage, side effects, location of metastases, type of treatment, comorbidities (assessed by Charlson Comorbidity Index and PS (ECOG). Calculation of the risk of systemic therapy toxicity will be based on the Cancer and Aging Research Group toxicity score with data from medical records and patient questionnaire.

**Demographic and patient-reported data**
Patient questionnaire and medical records will be used to obtain data including working and civil status, educational level, smoking and alcohol habits, weight loss prior to diagnosis or progression and during the study (kg/percentage), and prior and current physical activity level.

**Blinding procedure**
All physical tests, including the 30s-CST (primary outcome), will be conducted by the same two physiotherapists blinded for group allocation, and thus not involved in delivering the exercise intervention. A standardised test manual will be used to ensure uniformity.

**Sample size**
The sample size calculation is based on a minimal clinical important improvement (MCII) for the 30s-CST of 2.6 repetitions and an SD of 3. The SD is based on the previous studies using the 30s-CST in patients with advanced cancer.25 26 An MCII for the 30s-CST has not yet been established in patients with cancer but is suggested to be 2.6 in patients with osteoarthritis.27 With a type I error of 5% and a power of 90%, a total of 29 patients in each group are needed to be able to detect a between-group difference of 2.6 repetitions in the 30s-CST after the intervention (12 weeks).

The dropout rate is unknown in older patients with breast cancer. If the dropout rate is 40% throughout the study period, we anticipate it will be necessary to include up to a total of 100 patients.

**Statistical analyses**
Baseline characteristics will be presented separately for the intervention and control groups. Data from the results of the physical tests, body composition measures, blood samples and questionnaires will be reported as mean and 95% CI or as median and IQR, as appropriate. Feasibility measures (attrition, adherence, acceptability and adverse events) will be presented as numbers and percentages. Reasons for declining participation and dropouts will be described, if stated. Differences between groups in continuous data will be analysed using a repeated measurement analysis, adjusted for baseline scores and covariates (ie, treatment, physical activity, comorbidities and BMI) and allowing for interaction between time and intervention. Analysis of time to death (by cancer or other causes) will be carried out using the Kaplan-Meier estimator, competing risk analyses and Cox regression analyses. Between-group comparisons will be carried out using Grey’s test and the log-rank test. The overall risk of death will be estimated by a Cox proportional hazard regression and the cancer-related cause of death by cause-specific Cox proportional hazard regression. The significance level of all tests is set a p<0.05, and analyses will be carried out in SAS 9.4, STATA or R by a statistician in collaboration with the primary investigator.

**Data statement**
Technical appendix, statistical codes and dataset will be available at any time by contacting the corresponding author.

**Patient and public involvement**
Patients and/or public were not involved in designing this study.

**ETHICS AND DISSEMINATION**
The study protocol has been peer reviewed and approved by the Scientific Ethics Review Committee of the Capital Region of Denmark (VEK ref.: H-18021013). Any protocol modifications will be communicated to this Committee.

Due to ethical consideration on information burden, participants will be informed at a second visit to the oncological ward. Informed oral and written consent will be obtained from all participants before inclusion.

The intervention is not expected to cause adverse events and any potential adverse events are believed to be outweighed by the beneficial effects of the intervention.

Trial results will be communicated to all participants, if requested, disseminated by publications in peer-review journals and presented at relevant conferences.

**DISCUSSION**
Exercise-based intervention studies that include older patients with breast cancer receiving medical treatment are scarce,16 although physical activity is regarded as a safe and effective intervention in improving health-related QoL, as well as physiological, behvioural and physical outcomes among breast cancer survivors.28 Only a small number of minor adverse events have been reported,
and there is no evidence that physical activity interventions among women diagnosed with breast cancer can have harmful or negative effects. Exercise interventions among patients with breast cancer receiving medical treatment that include resistance training or a combination of resistance and aerobic training have been shown to reduce fatigue, symptoms of depression and improve QoL. Furthermore, exercise interventions have been shown to minimise decline in cardiorespiratory fitness and improve muscle strength, physical function, bone mineral density, sleep and shoulder range of motion. Resistance training alone in patients with breast cancer during adjuvant chemotherapy can significantly reverse sarcopenia and dynapenia.

Prior exercise-based intervention studies that have included patients with breast cancer are characterised by heterogeneity, especially regarding the type, duration and intensity of exercise. This gives rise to variations in the information on exercise interventions for this group, especially in terms of type and intensity. Therefore, the evidence-based ACSM guidelines were used for designing the intervention in this study. The intervention is based mainly on supervised PRT because of its known ability to counter the frequent side effects due to ageing, cancer and cancer treatment, especially cancer-related cachexia. Cancer-related cachexia is significantly associated with impairment of ADL and poorer survival in the geriatric oncology population. Furthermore, breast cancer and old age are associated with an increased inflammatory profile, leading to comorbidities and decreased physical function. Associations between inflammatory profile and exercise in older patients with breast cancer is an unexplored field and could lead to clinically relevant new knowledge.

Many older persons do not meet the recommended intake of 0.8 g/kg of protein, increased to at least 1.5 g/kg in the sarcopenic and cachectic population in their daily diet. Therefore, a protein supplement was included in the intervention to prevent further deficiencies in protein intake. Aerobic exercise at a light-to-moderate intensity is included in this study and measured using a pedometer which counts daily steps. To prevent increased energy demands, possibly causing weight loss, vigorous aerobic exercise is not included in this study. The absence of vigorous intensity cardiorespiratory training is in accordance with the ACSM guidelines, which state that adults should perform either moderate- (≥5 days/week), vigorous (≥3 days/week) intensity cardiorespiratory training or a combination.

A possible limitation of this study could be the potential heterogenous sample. The study was primarily designed for patients in adjuvant treatment. However, due to poor recruitment, inclusion criteria were broadened to also include patients receiving neoadjuvant and metastatic treatment. It may not be possible to perform subgroup analysis on different treatments, due to lack of power.

To minimise the burden of completing multiple questionnaires, a specific questionnaire regarding fatigue was not included in this study. However, MDASI and EORTC QLQ-C30 include questions regarding fatigue.

Exercise can influence a variety of recommended outcome measures of relevance to older women with breast cancer, including physical function, physical well-being and QoL; although few studies have included assessments of the latter two. Other outcome measures of importance to patients, healthcare stakeholders and practice are incidence of hospitalisation, reduction in cancer treatment toxicity and survival. The evidence-based intervention and a broad array of objective and patient-reported outcome measures recommended for this patient group are considered to be a strength in this study.

Exercise interventions that include older women with breast cancer receiving medical treatment is an unexplored field. The BREACE study could provide new valuable knowledge on early rehabilitation for this patient group, and the study’s intervention could possibly hinder or minimise side effects, decline in physical function and improve QoL in both the short and long term in this group of patients. Should the study prove effective, the pragmatic approach to the intervention and integration in the hospital and home setting is believed to be implementable in many older patients with breast cancer.

Author affiliations
1Department of Physiotherapy and Occupational Therapy, Herlev and Gentofte University Hospital, Herlev, Denmark
2Department of Oncology, Herlev and Gentofte University Hospital, Herlev, Denmark
3Department of Oncology and Hematology, Rigshospitalet, Copenhagen, Denmark
4Department of Medicine, Herlev and Gentofte University Hospital, Herlev, Denmark
5Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Kobenhavn, Denmark
6QD-Research Unit, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
7Department of Physiotherapy and Occupational Therapy, Herlev and Gentofte University Hospital, Hellerup, Denmark
8Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark
9Department of Clinical Physiotherapy and Nuclear Medicine, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark

Contributors Authorship follows the Vancouver guidelines. HHA, DLN, MKM, JSJ, CML, AV and IL designed the study. AV, A-MR and IL designed the intervention. HHA and IL wrote the manuscript, with support from DLN, MKM, JSJ, AV, CJ, BZ and A-MR. All authors read and approved the final manuscript.

Funding This work was supported by the VELUX Foundation (ID number 00018310). The VELUX Foundation (or other future funding organisations) will not have any role in defining the research question, study design or protocol, data collection, interpretation of data, or in drafting or approval of coming publications. There is no commercial or politically binding relationship between any members of the TOLCA (Translational and clinical research focused on older patients with cancer) project group and the VELUX Foundation.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) licence, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.


7
REFERENCES


